PRESS RELEASES<< Back
Chimerix to Announce Second Quarter 2017 Financial Results on August 7, 2017
DURHAM, N.C., July 31, 2017 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients, today announced that it will host a live conference call and audio webcast on Monday, August 7, 2017 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2017, and to provide a business overview.
To access the live conference call, please dial (877) 354-4056 (domestic) or (678) 809-1043 (international) at least five minutes prior to the start time, and refer to conference ID 54730100. A live audio webcast of the call will also be available on the Investors’ section of the Company's website, www.chimerix.com. An archived webcast will be available on the Chimerix website approximately two hours after the event.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. In addition, Chimerix has in early-stage development a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. For further information, please visit Chimerix's website, www.chimerix.com.
CONTACT: Investor Relations: email@example.com or Will O’Connor Stern Investor Relations Will@sternir.com 212-362-1200 Media: Becky Vonsiatsky W2O Group firstname.lastname@example.org 413-478-2003